Compare MasterCard Inc (MA) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs GeneDx Holdings Corp — how do they compare? MasterCard Inc trades at $589.14 (market cap $503.50B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: MasterCard Inc is far larger — about 249.3× GeneDx Holdings Corp's market cap, and MasterCard Inc pays a 0.61% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold MasterCard Inc for 134 Days and GeneDx Holdings Corp for 19 Days on average.
| MA | WGS | |
|---|---|---|
Market Cap | $503.50B | $2.02B |
Volume | 3,390,859 | 734,640 |
Sector | Financials | Health |
52-Week High | $599.86 | $167.51 |
52-Week Low | $471.55 | $34.51 |
Typical Hold Time | 134 Days | 19 Days |
Enterprise Value | $516.53B | $2.05B |
Dividend Yield | 0.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $574.76, up 0.82% today, with a bullish technical signal and strong fundamental performance. Revenue grew to $32.79B in 2025, with a net income margin of 46.34%. The stock is supported by consistent earnings beats and a robust analyst consensus of 80% buy ratings. Recent institutional buying activity and positive media coverage highlight investor confidence.
The outlook remains positive given Mastercard's high profitability, expanding digital payment initiatives, and upward earnings trajectory. Key risks include competitive disruption from new payment technologies and regulatory scrutiny. With a consensus price target of $666.67, the stock offers potential upside, but investors should monitor execution against growth targets.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
